cancer treatment

[Image: Black_Kira/istockphoto]

Lantern Pharma Preps 2026 Trial for Rare Pediatric Brain Cancer After FDA Guidance

by Quincy Preston | Oct 14, 2025

The North Texas biotech, which uses AI to accelerate cancer drug development, received FDA feedback to advance a new clinical study targeting a rare childhood brain tumor.

MORE►

Dallas Scores Another Disruptor in the Life Science Space

by Nicole Ward, DRC Data Journalist | Jun 24, 2025

At its Dallas Design District grand opening, Koya Medical marked the official move of its headquarters from California—bringing with it a wearable alternative to wall-powered compression therapy for vascular patients. “This is something that is different from anything that is out there,” says vascular surgeon and new CMO Tom Maldonado.

MORE►

16 Biotech Companies in Dallas-Fort Worth ‘Putting the Tech in Bio’ to Drive Breakthroughs

by Dallas Innovates | Staff Report | Mar 1, 2023

Dallas-Fort Worth is well known for its tech expertise. Now it being recognized as the place where technology meets life science—a convergence that’s driving rapid growth in the biotech ecosystem....

MORE►

David Halbert, founder, chairman, and CEO of Caris Life Sciences. [Photo: Caris]

Caris Life Sciences Raises $310M to Continue Rapidly Growing in the Precision Medicine Market

by Alex Edwards | Oct 27, 2020

The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.

MORE►

TWU Biology Team Granted a Patent for Anti-Cancer Compounds That Could Save Lives

by Alex Edwards | Oct 15, 2020

The novel invention from researchers at Texas Woman’s University in Denton could greatly contribute to cancer treatment research. The compounds can prevent the growth of breast, lung, and colon cancer cells.

MORE►

Caris Life Sciences Acquires Pharmatech to Pair Patients with Clinical Trials, Faster

by Payton Potter | May 2, 2019

Using a patient's molecular makeup, Caris and Pharmatech aim to find the perfect clinical trial for each cancer patient—and enroll them in as little as 10 days.

MORE►